Our work on a new therapeutic approach for multiple sclerosis is moving into the next stage, supported by the Czech investment fund LIFE BioCEEd Medical Investments.

The project builds on over a decade of research led by Ola, focused on mechanisms of damage and regeneration in the central nervous system. At its core is a small molecule (CF₃-7α,25-OHC) with the potential to both modulate the pathological immune response and promote myelin repair — a key process underlying neurological symptoms in MS.

The project originates from NCN-funded research, which made it possible to develop the initial concepts and validate them experimentally.

More details here: https://gumed.edu.pl/pl/aktualnosci/nauka/nowe-podejscie-terapeutyczne-w-leczeniu-stwardnienia-rozsianego-projekt-gumed-wchodzi-w-kolejny-etap-przy-udziale-funduszu-life-bioceed

https://www.bioceed.eu/portfolio

https://www.bioceed.eu/news/life-bioceed-invests-in-a-regenerative-therapeutic-approach-for-multiple-sclerosis

and media coverage here:

https://politykazdrowotna.com/artykul/nowa-terapia-na-stwardnienie-n2260642?srsltid=AfmBOooFsWqthxWx9tI5EX5oc8oVRiJIY59rFojYpWuq-VzuyNAryJPc

https://cowzdrowiu.pl/aktualnosci/post/nowa-terapia-sm-z-gdanska-blizej-badan-klinicznych

https://alertmedyczny.pl/gumed-rozwija-innowacyjna-terapie-sm-wsparcie-life-bioceed-przyspiesza-rozwoj/

https://www.mp.pl/sm/aktualnosci/403264,nowe-podejscie-terapeutyczne-w-leczeniu-sm